Evidence map›Paper›PMID 33392670›Full record

ReviewCurrent microbiology2021

Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19.

Arghyadeep Bhattacharjee, Manish Saha, Arpita Halder, Arka Debnath, Oindrilla Mukherjee

Abstract readReview
In one paragraph

Review in Current microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arghyadeep BhattacharjeeDepartment of Biotechnology, National Institute of Technology Durgapur, Mahatma Gandhi Road, A-Zone, Durgapur, West Bengal, 713209, India.
Manish SahaDepartment of Cardiology, R.G Kar Medical College & Hospital, 1, Khudiram Bose Sarani, Bidhan Sarani, Shyam Bazar, Kolkata, West Bengal, 700004, India.
Arpita HalderDepartment of Biotechnology, National Institute of Technology Durgapur, Mahatma Gandhi Road, A-Zone, Durgapur, West Bengal, 713209, India.
Arka DebnathDepartment of Biotechnology, SRM University, Mahatma Gandhi Road, Potheri, SRM Nagar, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
Oindrilla MukherjeeDepartment of Biotechnology, National Institute of Technology Durgapur, Mahatma Gandhi Road, A-Zone, Durgapur, West Bengal, 713209, India. oindrilla.mukherjee@bt.nitdgp.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The newly identified 2019 novel coronavirus (SARS-CoV-2) has become a public health concern globally posing a significant threat to human health and economy and creating an unprecedented crisis in all spheres of the global life. Emergence of new genotypes of SARS-CoV during the last few years has pointed out the limited efficacy of available vaccines and antivirals, constraining the global response to the COVID-19 outburst to largely monitoring/containment. There is high priority for treatment regimes and new potential therapeutic and vaccine strategies. Several candidates have shown promising outcomes in various in vitro and in vivo models. In addition, clinical trials are in progress to test conceivable therapies showing promising outcomes in various in vivo studies. Unfortunately, very little information is available in the scientific scope which offers details to the diverse strategies being targeted to fight the pandemic, particularly with respect to the molecular targets. This review article summarizes and highlights the ongoing advances and approaches that are being carried out across the globe in designing vaccines and novel therapeutics, with particular reference to the previous knowledge gained from other viral infections like with the earlier SARS and MERS-CoV. A detailed knowledge may pave the way to combat this pandemic COVID-19 as well as prevent similar deadly epidemics in future.

Indexed as

Antiviral AgentsCOVID-19COVID-19 VaccinesHumansPandemicsSARS-CoV-2Antiviral AgentsCOVID-19 Vaccines

Identifiers

PMID33392670
PMCPMC7779084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.